Navigation Links
QRxPharma Doses First Patients in Phase III Clinical Trial Program for its 'Dual Opioid' Pain Therapy
Date:11/26/2007

First study to focus on acute, post-surgical pain, with a follow-on safety extension trial to begin in late-2007

SYDNEY, Australia, Nov. 26 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX) announced today that a number of patients have been treated in the first of several clinical studies to be conducted as part of the Phase III development program for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy.

The initial clinical trial is a double-blind, placebo-controlled study designed to compare the efficacy and safety of four different dosage strengths of Q8003IR vs. placebo in a post-surgery, acute pain setting. The study is being conducted at 8 US clinical research sites and is targeted to enroll 250 patients experiencing moderate to severe pain following a scheduled surgical procedure (bunionectomy).

"Initiation of this Phase III clinical trial program not only demonstrates the Company's ability to deliver on its development milestones for Q8003IR in terms of budget and time-line projections, but also represents a significant step forward towards our goal of commercializing our first dual-opioid pain therapy in 2010," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.

The primary clinical endpoints for this acute, post-surgery pain study focus on pain relief and pain intensity scores vs. placebo over the first 48 hours post-surgery. Secondary endpoints include: (1) efficacy relating to the time to onset of analgesia and the duration of effect from a single oral dose; and (2) safety as measured by the incidence and intensity of opioid-related adverse events. A safety extension trial will immediately follow patient enrollment in this first trial to begin capturing longer-term patient safety data in support of our planned future New Drug Application (NDA) data submission package for Q8003IR.

Q8003IR is a patent-protected, immediate release dual-opioid product
'/>"/>

SOURCE QRxPharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
3. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
9. Tainted Chinese Food Ingredients First Discovered in 2005
10. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , N.J. and NEW BRUNSWICK, N.J., Sept. 30, 2014 ... agreement that allows Kessler Foundation and New Jersey ... biomedical research, education and patient care programs has ... and chief executive officer of Kessler Foundation and ... Jersey Health Foundation. "The experience of ...
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
... Aug. 23 /PRNewswire-FirstCall/ -- Today at ... FUJIFILM Medical Systems U.S.A., Inc. announced that it ... D-EVO™ flat panel detector.  As U.S. installations of ... departments will begin benefiting from the seamless transition ...
... today announced that it has signed an exclusive agreement ... tablets) 10 mcg.  Under the terms of the agreement, ... in the U.S. beginning August 2 through the company,s ... Vagifem® 10 mcg to the U.S. market earlier this ...
Cached Medicine Technology:FUJIFILM's FDR D-EVO™ is Now Available and Shipping 2Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg 2Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg 3
(Date:9/30/2014)... Somerset, N.J. (PRWEB) September 30, 2014 ... global provider of advanced delivery technologies and development ... today announced a full agenda for the 25th ... Paris, France, from October 6th to 9th. , ... and supply capability expansions during the show, including ...
(Date:9/30/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... on 5 reasons why relapse shouldn’t stand in the way ... a one-time event, like reaching the finish line of a ... “It’s an ongoing process and a lifelong commitment that will ...
(Date:9/30/2014)... devised a way to rapidly test hundreds of different ... discover promising new ways to deliver a class of ... DNA, to human patients. , In a study appearing ... used this technology to identify materials that can efficiently ... type of high-speed screen could help overcome one of ...
(Date:9/30/2014)... cells cannot multiply and cardiac muscles contain few ... itself after a heart attack. Now Tel Aviv ... standard in cardiac tissue engineering. , Dr. Tal ... TAU,s Department of Biotechnology, Department of Materials Science ... have been developing sophisticated micro- and nanotechnological tools ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 RISC ... IT Infrastructure analytics across data center, cloud and ... achieved an important milestone of helping more than ... for important projects such as IT infrastructure transformation, ... , The strong customer engagement rates and partner ...
Breaking Medicine News(10 mins):Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:New Best Drug Rehabilitation Blog Post Focuses on 5 Reasons Why Relapse Shouldn’t Stand in the Way of Recovery 2Health News:New Best Drug Rehabilitation Blog Post Focuses on 5 Reasons Why Relapse Shouldn’t Stand in the Way of Recovery 3Health News:High-speed drug screen 2Health News:High-speed drug screen 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 2Health News:RISC Networks Becomes First SaaS Cloud Readiness and IT Infrastructure Analytics Vendor to Surpass Milestone of 5,000 Engagements 3
... methodology behind WHO rankings, WASHINGTON, Feb. 26 ... in what could be,the final debate before the nominee ... be a topic of discussion. But as the two ... tales of people (invariably,swing state residents) encountered on the ...
... YORK (Feb. 26, 2008) -- As many as ... not respond to the standard first-line chemotherapy placed ... data. When this happens, typically, their only option ... at the Herbert Irving Comprehensive Cancer Center of ...
... Feb. 26 ULLICO Casualty Group (ULLICO,Casualty) has ... fiduciary and union liability insurance programs. Hudson is ... than $2,billion) by A.M. Best Company. Hudson is ... the holding company for one of the world,s,largest ...
... provoked soil-dwelling bacteria into producing a new type of ... in a battle for survival. , The antibiotic holds ... ulcers in humans. Also, figuring out the still murky ... help scientists develop strategies for finding other new antibiotics. ...
... Board: HFIT), a leading employee health improvement company,will report ... 31, 2007, on Wednesday, March 5, 2008, after the ... a conference call to discuss the,results the same day. ... and chief executive officer, and Wes Winnekins, chief financial,officer., ...
... 26 At Beverly Hills,Liposculpture, Dr. Alan Bittner ... safe breast reduction surgery that can reduce,breasts by ... The procedure,called liposculpture breast reduction, takes approximately 90 ... fat (more than 3 coke cans!) from each ...
Cached Medicine News:Health News:World Health Report Rankings Driven by Ideology, Skewed Data 2Health News:Study looks at new bladder cancer therapy for patients unresponsive to standard treatment 2Health News:ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance 2Health News:ULLICO Casualty Group Aligns with Hudson Insurance Company to Offer Fiduciary and Union Liability Insurance 3Health News:Bacterial 'battle for survival' leads to new antibiotic 2Health News:Bacterial 'battle for survival' leads to new antibiotic 3Health News:Health Fitness Corp. to Report Fourth Quarter and Year End 2007 Financial Results on March 5, 2008 2Health News:Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50% 2Health News:Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50% 3
Inquire...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of...
Medicine Products: